Revvity’s index inclusion and AI update draw investor focus

Revvity (RVTY) has come into focus after being added to the Russell 2500 Index and the Russell 2500 Value Benchmark, along with an update on new artificial intelligence capabilities within its Signals One software platform.

At a share price of $113.02, Revvity has seen a 14.1% 7 day share price return and 29.0% 90 day share price return, while the 5 year total shareholder return is down 26.5%. This suggests recent momentum contrasts with weaker longer term outcomes.

If Revvity’s AI update has caught your attention, it may be worth scanning for other researchers’ tools and infrastructure opportunities via Simply Wall St’s 40 healthcare AI stocks

With Revvity trading at $113.02, an intrinsic value estimate that sits about 17% higher and a value score of 2 raise a key question for you: is there still upside, or has the market already priced in future growth?

Most Popular Narrative: 50% Undervalued

Against Revvity’s last close at $113.02, the most followed valuation narrative points to a fair value near $113.64, implying the stock screens as materially undervalued once future cash flows and margins are factored in using an 8.3% discount rate.

Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Want to see what sits behind that margin reset and fair value call for Revvity? The narrative leans on measured revenue growth, rising earnings power and a rich future multiple to tie it all together.

Result: Fair Value of $113.64 (UNDERVALUED)

However, Revvity’s story is not risk free, as regulatory changes in China and softer academic funding both have the potential to pressure diagnostics demand and margins.

Another view on Revvity’s valuation

While the Simply Wall St DCF model suggests Revvity is trading about 17% below an estimated future cash flow value of $136.19, the current P/E of 52.7x is more than double the DCF implied fair ratio of 24.3x. Is the market paying too much for near term optimism, or is the model too cautious?

Investors weighing these two lenses can use them as a cross check on assumptions about Revvity’s earnings quality, growth and risk profile, then decide which picture feels closer to how they see the company today. Look into how the SWS DCF model arrives at its fair value.

Next Steps

With mixed signals around Revvity’s valuation, risks and rewards, the next move is yours. Act quickly by weighing both sides in the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Revvity?

If Revvity has sharpened your focus on valuation and quality, do not stop here. Fresh ideas across different styles can help balance your watchlist.

• Target potential mispricings across the market by reviewing companies highlighted in the 44 high quality undervalued stocks.
• Strengthen your income stream by scanning stocks featured in the 8 dividend fortresses.
• Prioritise resilience by checking companies grouped in the 69 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.